Hemorheological effects of pentoxifylline on disturbed flow behavior of blood in patients with cerebrovascular insufficiency.

The influence of pentoxifylline (11-18 mg/kg orally, Trental 400) on impaired hemorheologic conditions has been investigated in a total of 73 patients with CVI. Throughout a treatment period of 4 weeks, there was a significant improvement in red cell behavior and a significant inhibition of increased platelet aggregation; moreover, a fall in plasma fibrinogen and of blood viscosity has also been observed.